Funding Awarded
- Investigating the tumor metabolism-hypoxia-vasculature axis in the response of TNBC to immunotherapy Giorgia Colombo, Principal Investigator 2024 - 2026
- Targeting MALT1 to Enhance Anti-Lymphoma Immunity and Response to Immunotherapy awarded by National Cancer Institute Roberta Zappasodi, Principal Investigator 2023 - 2028
- Tumor-metabolism-driven therapies to overcome TNBC immune resistance awarded by Breast Cancer Alliance Inc. Roberta Zappasodi, Principal Investigator 2023 - 2025
- Targeting Unmet Needs For B-cell Lymphomas awarded by Leukemia & Lymphoma Society, Inc. Roberta Zappasodi, Co-Investigator 2022 - 2027
- Restoring lymphoma immunosurveillance by combined EZH2 inhibition and immunotherapy. awarded by Leukemia & Lymphoma Society, Inc. Roberta Zappasodi, Principal Investigator 2021 - 2024
- SRA with BMS awarded by Bristol-Myers Squibb Company Principal Investigator 2021 - 2024
- Image-guided Trp-IDO/TDO-Kyn-AHR pathway inhibition, combined with immunotherapy awarded by National Cancer Institute Inna Serganova, Co-Investigator 2022 - 2026
- Exploiting tumor metabolism to optimize T cell therapy awarded by National Cancer Institute Inna Serganova, Principal Investigator 2021 - 2024
- SRA with BMS awarded by Bristol-Myers Squibb Company Roberta Zappasodi & Inna Serganova, Principal Investigators 2021 - 2024
